Abstract
Inhaled corticosteroids are effective and safe treatments for childhood asthma in standard doses, yet at high dosages they may be associated with adverse events and suboptimal outcomes; add-on therapy is, therefore, recommended to minimise their use. We quantified prescribing of high-dose inhaled corticosteroids and add-on therapy in children in July 2003 and found that high-dose inhaled corticosteroids were prescribed to 10% of children aged 5-11 years and 6% of under-5's who were treated for asthma. Add-on therapy was lacking for almost half of these individuals. Some children were receiving treatment not in accord with current licences and evidence-based recommendations and, as such, may be at risk of adverse outcomes.
Original language | English |
---|---|
Pages (from-to) | 788-790 |
Number of pages | 3 |
Journal | The British Journal of General Practice |
Volume | 531 |
Publication status | Published - 1 Oct 2006 |
Keywords
- asthma
- child
- database
- pharmacoepidemiology
- prescriptions, drug
- children